(Q44948545)

7 December 2017

title

Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis (English)

1 reference

7 December 2017

0 references

0 references

N A Jarad

1

1 reference

7 December 2017

K Giles

series ordinal

2

1 reference

7 December 2017

publication date

1 January 2008

1 reference

Chronic Respiratory Disease

7 December 2017

published in

1 reference

7 December 2017

volume

5

1 reference

7 December 2017

issue

1

1 reference

7 December 2017

page(s)

29-33

1 reference

Management of pulmonary disease in patients with cystic fibrosis

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Predictive 5-year survivorship model of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Effect of high-dose ibuprofen in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Defining a pulmonary exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Some consensus but little evidence: guidelines on management of pleural infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

The cost of medical care for patients with cystic fibrosis in a health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Wasting as an independent predictor of mortality in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479972307085635

21 January 2018

Identifiers

DOI

10.1177/1479972307085635

1 reference

7 December 2017

1 reference